Jake Smith is a postdoctoral scientist in the TB Discovery Research group at IDRI. He works in a team exploring new molecules to treat tuberculosis; specifically, he is focused on the design, selection and synthesis of molecules for series in the discovery pipeline.
Her doctoral research focused on developing a next-generation protein-polymer conjugation technology to improve the delivery of therapeutic biologics and to address some of the limitations of the current gold-standard PEGylation technology. Stacey has also completed an internship at BASF in Germany where she formulated and tested novel herbicides in plants.
Aude is a Clinical Trial Manager in the Clinical team. Her role includes project management and clinical trial management to support the development of IDRI’s vaccine candidates. She contributed to the success of the recent clinical trials conducted in the U.S., Sudan, Peru and South Africa. She started her career in the pharmaceutical industry in the early 90s, working at Astra, then Aventis in Paris, France, for the clinical development of respiratory and allergic diseases compounds.
Neal received his Ph.D. from the Molecular and Cellular Biology program at the University of Washington in 2005, where he worked in the laboratory of Dr. Dusty Miller, focusing on development of new viral vectors for use in gene therapy. He carried out his post-doctoral studies in the Influenza Division at the Centers for Disease Control and Prevention (CDC) in Atlanta under the supervision of Dr. Terrence Tumpey and Dr. Jacqueline Katz, where he worked to understand transmissibility of highly pathogenic influenza viruses.
Neal Van Hoeven is a Senior Scientist at IDRI. Neal’s work is focused on pre-clinical downselection and evaluation of vaccine adjuvants for several emerging viral diseases. His ongoing research projects include programs to develop adjuvants for use with H5N1 pandemic influenza antigens as well as West Nile Virus vaccines. In addition, he is interested in understanding the effect that adjuvants have on the generation and maturation of antiviral antibodies, and is working to develop a number of high-throughput techniques for evaluation of complex antibody responses following vaccination in animals and humans.
Shilah received her BSc in Environmental Science/Toxicology from Western Washington University and her PhD in Chemistry from Portland State University. Her graduate research focused on the enzymology of tRNA modification in bacteria. Prior to joining IDRI in 2013, Shilah worked at Portland State University as a Postdoctoral Scientist studying the metabolic pathways and enzymes involved in the generation of natural products (drug discovery) and olefins (biofuels development).
Julie Early is a Scientist I in the TB Drug Discovery Group. Julie's work involves several aspects of early stages of drug discovery for tuberculosis. Her work focusses on microbiological aspects including assay development, high throughput screening, and progression of compound series using numerous biological techniques to profile compounds. She is also involved in identifying the mechanism of action of anti-tubercular compounds.
Somsundaram received a BS in Pharmaceutical Sciences from University of Mumbai, India, and a MS in Pharmacy from University Department of Chemical Technology, India. He went on to earn a PhD under the mentorship of Dr. Pui-kai Li and Dr. Chenglong Li from the College of Pharmacy at the Ohio State University. His thesis work focused on developing novel small molecule inhibitors against protein targets such as survivin and STAT3 that are essential for progression and survival of cancer.
Somsundaram N. Chettiar is a Postdoctoral Scientist in the TB Discovery Research group at IDRI. His work focuses on the development of novel small molecules for the treatment of tuberculosis.
Shilah Bonnett is a Scientist I in the TB Drug Discovery group at IDRI. Shilah's work focuses on the development of target based high throughput screens to identify potential drug candidates for the treatment of tuberculosis.
Mark is also an Affiliate Assistant Professor in the University of Washington, Department of Global Health Interdisciplinary Pathobiology Program. He has published over 25 peer-reviewed articles in the fields of immunology and vaccine development. He is a member of the American Association of Immunologists and serves on the editorial board of Frontiers in NK Cell Biology.
Mark Orr, Ph.D. is an immunologist in the Pre-Clinical Biology group. As a Senior Scientist and Principal Investigator at IDRI his research interests include:
Joshua Odingo is the Director of Chemistry in the TB Drug Discovery Group. Joshua is an organic/medicinal chemist with many years of experience in small-molecule drug discovery. His work focuses on the application of medicinal chemistry to the development of novel agents for the treatment of tuberculosis. He is also working on tool molecules for target identification and interrogating disease biology.
Eduard earned his BA in Biochemistry and Molecular Biology from Franklin & Marshall College and his PhD in Biochemistry and Structural Biology from Stony Brook University. His doctoral work with Dr. Peter J. Tonge focused on elucidating the mechanism of GFP chromophore maturation using protein semi-synthesis. He went on to a postdoctoral position with Dr. Iwao Ojima evaluating anti-tubercular compound series that inhibit the cell division protein FtsZ and screening computationally designed small molecule inhibitors of Botulinum neurotoxin.